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In humans, advanced mast cell (MC) neoplasms are rare malignancies with a poor prognosis.
Only a few preclinical models are available, and current treatment options are limited. In dogs,
MC neoplasms are the most frequent malignant skin tumours. Unlike low-grade MC neoplasms,
high-grade MC disorders usually have a poor prognosis with short survival. In both species, neo-
plastic MCs display activating KIT mutations, which are considered to contribute to disease evo-
lution. Therefore, tyrosine kinase inhibitors against KIT have been developed. Unfortunately,
clinical responses are unpredictable and often transient, which remains a clinical challenge in
both species. Therefore, current efforts focus on the development of new improved treatment
strategies. The field of comparative oncology may assist in these efforts and accelerate human
and canine research regarding diagnosis, prognostication, and novel therapies. In this article, we
review the current status of comparative oncology approaches and perspectives in the field of
MC neoplasms.
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Mast cell (MC) neoplasms are haematopoietic disorders characterized
by uncontrolled expansion and accumulation of neoplastic mast cells
(MCs) in various organ systems.1–7 In humans, the most frequently
affected organs in systemic mastocytosis (SM) are the skin, bone mar-
row (BM), liver and spleen. Both indolent and aggressive variants of
SM have been described.1–10 Indolent variants include patients with
cutaneous mastocytosis (CM) and indolent SM (ISM). Advanced forms
of SM can be divided into aggressive SM (ASM), SM with an associ-
ated hematologic neoplasm (SM-AHN) and MC leukaemia
(MCL).1–4,8–10 MC sarcoma (MCS) is an extremely rare, localized form
of advanced mastocytosis in humans. Whereas patients with ISM have
an excellent prognosis with normal life-expectancy,11 patients with
advanced SM or MCS have a poor prognosis with short survival times
(STs).2–4,12,13 For example, Lim and colleagues reported that patients
with ASM have a median ST of 41 months, patients with SM-AHN
have a median ST of 24 months, and MCL patients have a median ST
of 2 months.12
In the canine system, cutaneous MC tumours (MCTs) are fre-
quently detected and can be divided into less aggressive and more
aggressive variants. The aggressive MCT can involve regional lymph
nodes and/or visceral organs.5–7,14 It is worth noting that MCTs in
dogs are the most frequent malignant skin tumours.5–7 Whereas his-
tological low-grade MCTs have a good-to-excellent prognosis, metas-
tasized and/or high-grade canine MCTs have a poor prognosis with
short STs.5–7
In dogs as well as in humans, it is of considerable importance to
establish the correct diagnosis and to define whether the patient has
an indolent MC neoplasm or an advanced category of the disease.
During the past few decades, the pathogenesis and molecular
mechanisms underlying disease evolution and progression of SM have
been analysed. In both species, neoplastic MCs display activating KIT
mutations that are considered to contribute to disease
evolution.1–4,15–20 Based on this concept, various tyrosine kinase
inhibitors (TKI) directed against KIT have been developed with the
hope that these agents can act as disease-modifying drugs.21–30
Unfortunately, clinical responses are unpredictable and often transient
in both species, which remains a clinical challenge in daily
practice.31–40 Therefore, current efforts focus on deciphering other
molecular pathways involved in the pathogenesis of SM in order to
establish new treatment strategies.
Comparative oncology is an emerging field that is based on the
assumption that the biochemical processes and pathogenesis contrib-
uting to the evolution and progression of spontaneous malignancies in
human and animal species are often comparable and that these simi-
larities can be exploited in basic and translational science.41–44 Based
on this assumption, many different projects in the field of comparative
oncology have been initiated.44–46 One emerging example with future
potential might be research on human and canine MC neoplasms.47,48
As mentioned before, these neoplasms have several aspects in
common, such as KIT mutations and a poor outcome in advanced
stages.
There is hope that the field of comparative oncology can assist in
our efforts to accelerate human and canine research on MCs and to
improve diagnosis, prognostication and, ultimately, therapy in MC
neoplasms. However, a number of questions regarding classification,
prognostication and therapy of advanced MC disorders in both spe-
cies remain. For example, it remains to be explored whether the diag-
nostic criteria and prognostic parameters that have recently been
established in human MC neoplasms, can be employed in a similar,
analogous way in the canine system.
In the present article, we review the current status of compara-
tive oncology approaches in the field of MC neoplasms, with special
focus on diagnosis, prognostication and standard treatment of
patients with MC neoplasm in humans and dogs.
2 | CLASSIFICATION OF MC NEOPLASMS
AND MINIMAL DIAGNOSTIC CRITERIA
Whereas minimal diagnostic criteria for SM have been established in
humans, no such criteria have been validated in canine MCT so far. In
human SM, the major diagnostic criterion relates to the multi-focal
dense infiltrates of MCs in the BM and other extracutaneous
organs.2,49–54 Minor criteria include the abnormal (often spindle-
shaped) morphology of MC, expression of CD2 and/or CD25 in MCs,
KIT-activating mutations at codon 816 of KIT and elevated serum
tryptase levels (>20 ng/mL).2,49–54 When at least one major and one
minor or at least three minor criteria are fulfilled, the diagnosis of SM
can be established.2,49–54 At present, it remains unknown whether
disease-related parameters that have already been proven to serve as
robust diagnostic parameters in human MC neoplasms, such as abnor-
mal expression of CD25 on neoplastic MCs or certain KIT mutations,
should undergo validation in dogs with MCTs.55,56 In addition, it
remains unknown whether elevated serum tryptase levels might serve
as diagnostic and follow-up parameters in dogs with MCTs in the
same way as in human MC neoplasms. If one or more of these
markers were determined to be of diagnostic value, these parameters
could be employed as additional diagnostic criteria in dogs in future
proposals. For the moment, the diagnostic tools available to classify
canine MCTs are morphological assessments, histochemical studies
(such as toluidine blue) and immunohistochemical investigations of
neoplastic MCs, which may provide a solid basis for forthcoming com-
parative oncology studies (Figure 1).57–60
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While the diagnosis of canine MCT can be made by a fine-needle
aspiration-based cytology in a majority of the cases, histological grad-
ing of MCT requires histological examinations of the primary tumour
site. Occasionally, immunohistochemistry may be necessary to con-
firm the diagnosis, especially when MCT is undifferentiated. Potential
diagnostic criteria for canine MCTs and a comparison with diagnostic
criteria for human SM are shown in Table 1.
3 | CLINICAL AND HISTOLOGICAL
PRESENTATION OF MC NEOPLASMS
Depending on the affected organ-system(s), human mastocytosis can
be divided into CM, SM, and localized MCTs.2,49–54 In the human sys-
tem, the classification of MC neoplasms proposed by the World
Health Organization discriminates between several distinct sub-
variants of CM and SM (Table 2). CM is defined by typical features of
cutaneous lesions, a diagnostic skin-histology, and the absence of cri-
teria sufficient to establish the diagnosis SM.2,8,49–52,61 A positive
Darier's sign supports the conclusion that the patient is suffering from
CM. However, identical cutaneous lesions are also seen in SM
(Table 1). Therefore, the lesion is described as mastocytosis in the skin
(MIS), and only a BM examination can clarify the final diagnosis
(CM or SM) in adults.2,8,49–52,61 It is noteworthy that a minimal infiltra-
tion of the BM with neoplastic MCs may be well detected in
CM. Even if two minor SM criteria (but no major SM criterion) are
found in these patients, the diagnosis remains CM. 2,8,49–52,61 How-
ever, once three minor criteria are documented or at least one major
and one minor criteria are found, the final diagnosis is SM.2,49–52 SM
variants that have a grave prognosis (SM-AHN, ASM, and MCL) are
also referred to as advanced SM. The major criteria for advanced SM
are the documented presence of SM-induced organ damage, also
known as C-findings (Table 3).2,49–52 Such C-findings include marked
persistent cytopenia, hepatic disease with elevated liver enzymes and
ascites, marked osteolyses (with or without pathologic fractures), or
malabsorption with hypalbuminemia and weight loss.2,49–52
In veterinary oncology, the most frequent clinical presentation of
MC neoplasms in dogs is a solitary cutaneous nodule (Figure 1).5–7
MCTs can have a very heterogeneous appearance, not always accom-
panied by a positive Darier's sign, and the diagnosis of MCT can usu-
ally be established by a cytological examination of a fine-needle
aspiration.5–7 However, fine-needle biopsy-derived cytology is not
sufficient to determine the grade of the MCT. Therefore, an additional
histological examination of the lesion is mandatory to determine the
grade of the disease and thus to anticipate the behavior of the MCT
in dogs. A number of clinical, molecular, and histopathological vari-
ables are considered to be of prognostic significance in canine MCTs
(Table S1). The first grading system was established by Patnaik et al57
in 1984 (Table S2). This classification system divides canine cutaneous
MCTs into three grades, namely, grade 1 with well-differentiated mor-
phology, grade 2 with intermediately differentiated cells, and grade
3 with poorly differentiated MCs.57 Although this grading system cor-
relates with the clinical outcome of patients, its practical application
showed some inconsistencies because of inter-observer varia-
tions.58,62,63 Therefore, a 2-tier histopathological grading system has
been proposed by Kiupel et al58 in 2011 (Table S3), with the aim to
improve the Patnaik system regarding prognostication of patients.
Nonetheless, it has been shown that approximately 15% to 20% of
dogs with Kiupel low-grade MCTs have metastatic disease at
presentation,64 suggesting that there is still a need for better prognos-
tication and an improved grading system in cutaneous MCTs, and for
the moment, many centres are using both the Patnaik and Kiupel
prognostication model in individual canine MCT patients. In the
FIGURE 1 Human and dog mast cell neoplasms. A, Skin involvement
in a patient with indolent systemic mastocytosis. B, Disseminated
cutaneous lesions of mastocytoma (grade 1 according to the Patnaik
Scheme and low-grade according to the Kiupel Scheme) in a
Doberman pinscher. C and D, Localized cutaneous mastocytoma
lesions in two different dogs. E, Immunohistochemical detection of
neoplastic mast cells in a cutaneous mastocytoma lesion using an
antibody against KIT. F, Infiltration of the bone marrow with
neoplastic mast cells visualized by tryptase-staining in a human
patient with aggressive systemic mastocytosis. G, KIT-positive mast
cells in a canine patient with multiple cutaneous mastocytoma. H,
KIT-positive mast cells in the bone marrow of human patient with
advanced mastocytosis. Original magnifications: E, F: ×200; G, H:
×600 [Colour figure can be viewed at wileyonlinelibrary.com]
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future, a refined prognostic grading system that includes laboratory
and molecular parameters may be developed in canine MCTs.
Whether KIT mutations and/or elevated tryptase levels are of prog-
nostic significance in canine MCTs, remains at present unknown.
4 | DETECTION OF KIT EXPRESSION AND
EVALUATION OF THE KIT MUTATIONAL
STATUS
In the human system, KIT is employed as a surface marker to detect
normal and neoplastic MCs (KIT+/CD34-) by flow
cytometry.2,8,49–52,61 In addition, KIT is employed together with tryp-
tase to detect and enumerate neoplastic MCs in the BM of patients
with SM by immunohistochemistry.65,66 In adult patients with SM, the
activating KIT mutation D816V is detected in a vast majority of cases.
Using highly sensitive polymerase chain reaction techniques, KIT
D816V can be detected in the BM and in the peripheral blood of most
adult human patients with SM.67–69 Therefore, KIT D816V not only
serves as a disease-related criterion but can also be employed as a PB
screening biomarker for patients with suspected SM.67 However, in a
smaller subset of patients with SM, other KIT mutations (in codons
other than 816) or no KIT mutations are found.62 In these patients,
sequencing studies of the whole KIT structure are sometimes recom-
mended.67 However, these studies are laborious and therefore are not
regarded as standard practice.
In dogs, immunohistochemical staining for KIT is of prognostic
value, as different staining patterns correlate with recurrence-rate and
TABLE 1 Established and potential diagnostic criteria in human and canine mast cell neoplasms
Marker/feature
Employed as diagnostic criterion in
Human systemic mastocytosis Canine mast cell tumour
Typical skin infiltrates –a –a
Histology of mast cell infiltrate + +
Abnormal morphology of mast cells + +
Basal serum tryptase level + –
KIT mutations + –b
Expression of CD2 or CD25 in mast cells + –
Expression of CD30 in mast cells –c –c
a Typical skin lesions and a positive Darier's sign are diagnostic criteria of human cutaneous mastocytosis and mastocytosis in the skin in those who have
systemic mastocytosis. In canines, a positive Darier sign can suggest the presence of a mast cell tumour, but the diagnosis of a mast cell tumour has to be
confirmed by cytology and/or histology in all cases.
b The presence of KIT mutations (exons 8, 9, and 11) can confirm the presence of a mast cell neoplasm, but is not yet regarded as a disease-related diagnos-
tic criterion.
c CD30 is aberrantly expressed on neoplastic mast cells and is a new emerging disease-related parameter and potential new criterion of systemic mastocy-
tosis in humans. Whether CD2, CD25, or CD30 can be employed as diagnostic criteria for canine mast cell tumours remains so far unknown. At least in
the human system, CD30 is expected to become a new minor criterion for systemic mastocytosis.
TABLE 2 Classification systems for human mastocytosis according to the WHO criteria
Variant and sub-variant(s) Abbreviation Minimal diagnostic criteria
Systemic mastocytosis SM SM criteria fulfilleda: at least one major and one minor or at least three
minor SM criteriaa (cutaneous involvement)
Indolent SM ISM No C-findingb, <2 B-findingsb, no AHN, MCs <20% in BM smears
BM mastocytosis BMM Same as ISM but without skin lesions
Smouldering SM SSM No C-findingb, 2 or 3 B-findingsb, no AHN, MCs <20% in BM smears
SM with an AHN SM-AHN Criteria for SM and for an AHN are fulfilledc
Aggressive SM ASM One or more C-findingsb and MC <20% on BM smears
Classical ASM ASM <5% MCs in BM smears
ASM in transformation ASM-t 5%-19% MCs in BM smears
MC leukaemia MCL ≥20% MCs in BM smears
Aleukemic MCL <10% MCs in peripheral blood
Chronic MCL No C-findingb
Acute MCL One or more C-findingsb
MC sarcoma MCS Local aggressive MC tumour, SM criteria not fulfilled
Extracutaneous mastocytomad Local benign MC tumour, SM criteria not fulfilled
Abbreviations: AHN, associated hematologic neoplasm; BM, bone marrow; MC, mast cell; WHO, World Health Organization.
The classification presented is based on the WHO proposal of 2001,2,49 2008,50 and 2017.52–54 Consensus criteria were first published in 2001,2 and were
later confirmed by the same group in 2007 and 2012.51,61
a Minimal criteria to diagnose SM (SM criteria) are shown in Table 3.
b B-findings and C-findings are listed in Table 3.
c The AHN component of disease is classified according to WHO criteria.
d Extracutaneous mastocytomas are exceptionally rare.
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survival in MCT.59 In contrast to the human system, a number of dif-
ferent KIT mutations are detectable in dogs with MCT.18–20 Therefore,
a more detailed evaluation of the KIT gene may be clinically helpful. A
full sequencing profile of the KIT gene is not standard in daily veteri-
nary practice. However, screening for a limited panel of KIT mutations
known to be clinically relevant (activating) and to occur recurrently
(in exon 8, 9, and 11 of KIT) in MCTs is recommended when the assay
is available.60,70,71
5 | STAGING INVESTIGATIONS IN
PATIENTS WITH MC NEOPLASMS
In the human system, involvement of the BM is always documented
by analysing BM biopsy samples by histomorphological and immuno-
histochemical studies and BM aspirate samples by cytomorphological,
flow cytometric, cytogenetic and molecular studies.2,49–54,61,65,66,72
Standard immunohistochemical markers applied for the detection and
enumeration of MCs in the BM (or other organs) are KIT (CD117) and
tryptase (Figure 1). Other organ systems are usually not examined by
histological studies, unless the aetiology of organopathy/organome-
galy remains uncertain or the patient is suffering from a sarcoma-like
disease (MC sarcoma). However, in all patients, the size of the liver
and spleen is determined by ultrasound or computed tomography
(CT).61 In addition, the sizes of the involved lymph nodes, when
enlarged, are measured by ultrasound and/or CT. Bone involvement
with osteopenia or osteoporosis should be determined by osteodensi-
tometry in all cases with SM.61 Osteopenia is quite frequently
detected in human patients with SM, and if not treated appropriately
most of these patients progress to osteoporosis that may be compli-
cated by pathologic bone fractures.2,61 Osteopenia/osteoporosis can
occur in any form/variant of SM. By contrast, large osteolyses are
rarely seen in SM and are confined to patients with advanced MC dis-
ease.2,61 In case of suspected focal lesions and in advanced SM, an
x-ray of all bones is usually recommended. Finally, the skin is exam-
ined in detail by inspection (and by photography if possible) in all
patients.11,61
In the canine system, clinical staging includes a complete blood
count with differential counts, serum chemistry and cytological or his-
tological and immunohistochemical studies of the primary organ site
and of the secondary (cutaneous or extracutaneous, metastatic)
lesion(s) (Figure 1).57,58 Fine-needle aspiration biopsies of regional
lymph nodes (even if normal in size), abdominal ultrasound (with or
without fine-needle aspiration of liver and spleen regardless of the
sonographic appearance) and thoracic radiography are usually per-
formed.64,73 In the majority of dogs, MCTs disseminate first into the
regional lymph nodes, then to the spleen and liver, and finally into
other visceral organs, whereas lung involvement is rare.74 In case of
major blood count abnormalities and/or visceral involvement, a BM
examination, including cytology (in BM smears), histology (morpho-
logic and immunohistochemical studies) is often recommended.75,76 A
detailed investigation of the BM in all dogs with MCTs is unlikely to
be clinically helpful as the vast majority of cases are presented with
solitary, low to intermediate grade tumours that are locally confined
and do not involve the marrow compartment. Whether BM assess-
ment in patients presenting with systemic illness, with negative prog-
nostic indices or for whom blood dyscrasias are present on routine
complete blood count can improve the staging system and treatment
recommendation, remains to be explored in future investigations.
Interestingly, unlike human patients with SM, neither osteopenia/
osteoporosis nor osteolyses is detected in canine patients with MCT.
Additional parameters, such as immunohistochemical markers (eg,
CD25), KIT mutations, and other molecular markers are employed suc-
cessfully in the diagnosis and prognostication of MC neoplasms in the
human system but so far not in the canine system. Whether charac-
terization of such parameters can be helpful in the diagnosis (primary
tumour site), grading (primary tumour and other involved organs),
TABLE 3 B-findings and C-findings recorded in human patients with SMa
B-findings = Indicate a high burden of MCs and expansion of the neoplastic process into multiple haematopoietic lineages without impairment of
organ function
Mnemonic: B = borderline benign (be watchful)
1. MC infiltration grade in the BM >30% by histology and basal serum tryptase level > 200 ng/mL
2. Hypercellular BM with loss of fat cells, discrete signs of dysmyelopoiesis without substantial cytopenias or WHO criteria for an MDS or MPN
3. Organomegaly: Palpable hepatomegaly, splenomegaly, or lymphadenopathy (on CT or ultrasound: >2 cm) without impaired organ function
C-findings = Indicate organ damage produced by MC infiltration (should be confirmed by biopsy if possible)
Mnemonic: C = consider cytoreduction
1. Cytopenia(s): ANC < 1000/μL or Hb < 10 g/dL or PLT < 100 000/μL
2. Hepatomegaly with ascites and impaired liver function
3. Palpable splenomegaly with associated hypersplenism
4. Malabsorption with hypoalbuminemia and weight loss
5. Skeletal lesions: Large-sized osteolyses with pathologic fractures
6. Life-threatening organ damage in other organ systems that is caused by local MC infiltration in tissues
Abbreviations: ANC, absolute neutrophil count; BM, bone marrow; ISM, indolent SM; MC, mast cell(s); MDS, myelodysplastic syndrome; MPN, myeloprolif-
erative neoplasm; PLT, platelets; WHO, World Health Organization.
a In SM patients in whom less than two B-findings and no C-finding are detected (category A), the diagnosis indolent SM can be established. When two or
more B-findings but no C-findings are present, the diagnosis is smouldering SM; and when 1 or more C-findings (+/− B-findings) are detected, the final
diagnosis is either aggressive SM (<20% MCs in BM smears) or MC leukaemia (MCs ≥20% on marrow smears) (see also Table 1B).
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staging (investigations of BM, blood and/or other organs), and/or
prognostication of canine MCTs remain to be determined in future
studies.
6 | UTILITY OF TRYPTASE AND OTHER
DISEASE PARAMETERS DURING FOLLOW-UP
In the human system, the basal serum tryptase level is a robust and
widely used follow-up parameter for patients with SM.77–80 In partic-
ular, tryptase is a serine protease that is produced and stored almost
exclusively in MCs and is secreted from resting MCs into plasma in a
constitutive manner.81,82 As a result, the basal serum tryptase level
reflects the total body burden of MCs in healthy individuals (normal
physiologic baseline: 1-15 ng/mL) and in patients with mastocytosis.82
In contrast, patients with CM generally have basal serum tryptase
levels within the normal range, clearly elevated tryptase levels
(>20 ng/mL) are almost invariably found in patients with SM and
therefore also serve as a minor diagnostic criterion of SM.49 In addi-
tion, the tryptase level is an important follow-up parameter in SM.61
Likewise, whereas patients with ISM have stable tryptase levels, a
steadily increasing basal serum tryptase is indicative of advanced SM
and/or disease progression. Furthermore, effective therapy is usually
accompanied by a decrease in the serum tryptase level.31,35–37,83
In addition, blood counts and (other) serum chemistry parameters,
such as alkaline phosphatase levels, are employed in the follow-up of
human patients with SM.61 Furthermore, liver and spleen size
(by ultrasound), lymph nodes, and the osteodensitometry (T score) are
measured routinely in the follow-up of patients with SM.61
In dogs, physical examination, in particular investigating the initial
location(s) of the MCTs and regional lymph nodes, determination of
blood counts and serum chemistry parameters, and abdominal ultra-
sound, are standard in the follow-up of MCT patients.75 At present,
no MC-specific serum- or plasma markers are available that could be
employed as follow-up parameters for dogs with MCTs. Whether the
inclusion of serologic MC-related follow-up parameters (like serum
tryptase) would be of value for determining the course of canine MCT
and for evaluation of responses to conventional or novel therapies
remains to be determined in future studies.
6.1 | Treatment of Advanced SM and selection of
anti-neoplastic drugs
In human patients with advanced MC neoplasm with slow progres-
sion, interferon-alpha (IFN-A) or cladribine (2CdA) have been consid-
ered as first-line therapy with response rates ranging between 10%
and 30%.83–86 In patients with rapidly progressing ASM and MCL,
more intensive therapy is required. In patients who are fit and eligible,
polychemotherapy containing fludarabine or 2CdA, often in combina-
tion with cytosine arabinoside (ARA-C), are recommended, and in case
of a sufficient response (clear cytoreduction), haematopoietic stem-
cell transplantation (SCT) should be considered.37,49,87,88 In patients
with poor performance status, 2CdA or hydroxyurea can be used as
palliate drugs. A more recent approach is to apply targeted drugs
directed against KIT D816V.34–37 Midostaurin has recently been
described to exert major disease-modifying activity in patients with
advanced SM including MCL.35,37 In addition, midostaurin is useful for
cytoreducing tumour load in patients with advanced SM prior to
SCT.37 In patients with MC sarcoma, the treatment recommendation
is similar to that in MCL because most of these patients transform to
ASM or MCL within weeks or months.37,49,87 In addition to chemo-
therapy, radiation therapy may be applied in MCS patients.37,49,87
However, most patients with MCS die within a short time-interval
despite intensive therapy.
In dogs with resectable MCTs without distant metastasis, surgical
intervention is the first-line therapy, especially for solitary grade I
MCTs.7 In cases of incomplete resection (“dirty margins”), re-excision
is recommended whenever possible.89 If re-excision is considered
impossible because of diffuse infiltration or massive tumour expan-
sion, post-surgical radiation therapy is required, and in high-grade
TABLE 4 Standard interventional therapies in advanced MC neoplasms in human and dogs
Development status and indication in
Drug/therapy Human patients Canine patients
Imatinib Approved for the treatment of aggressive
SM without D816V KIT mutant or with
unknown KIT mutation status
Used off-label for therapy of advanced MC
tumours in Japan
Cladribine (2CdA) Orphan drug approval n.a.
Midostaurin Approved for the treatment of advanced,
including ASM and MCL
n.a.
Toceranib Approved for therapy of canine non
resectable Patnaik grade 2/3 MCTs
(by EMA and FDA)
Masitinib Advanced SM without KIT D816V +/−
severe mediator symptoms
Approved for therapy of canine non
resectable Patnaik grade 2/3 MCTs with
KIT mutations (by EMA)
Polychemotherapy CT like in AML VBL/Pred; CCNU/Pred, also in combination
with TKI
SCT Standard in ASM-t and MCL after debulking
in young and fit patients
Not available in daily practice
Abbreviations: ASM, aggressive systemic mastocytosis; CCNU, chlorethyl-cyclohexyl-nitroso-urea, lomustine; CT like in AML, chemotherapy like in acute
myelocytic leukaemia; EMA, European Medicines Agency; FDA, Food and Drug Administration; MC, mast cell; MCL, mast cell leukaemia; n.a., not analysed;
Pred., prednisolone; SCT, haematopoietic stem-cell transplantation; SM, systemic mastocytosis; TKI, tyrosine kinase inhibitor; VBL, vinblastine.
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and/or metastasized MCT, radiation is usually combined with systemic
anti-neoplastic therapy.90,91 In dogs with high-grade metastasized or
unresectable MCTs, first-line treatment often consists of TKI therapy
using masitinib (EU), toceranib (US, EU) or imatinib (Japan) or cytore-
ductive chemotherapeutics (eg, vinblastine, lomustine; often in combi-
nation with steroids).38–40 More recently, the combination of
toceranib with radiation therapy has been described to be an effective
anti-neoplastic treatment approach for dogs with MCTs, including
high-grade MCTs.92 In case of primary or secondary resistance, differ-
ent chemotherapy protocols using alternative cytoreductive drugs or
combinations with TKI are prescribed.93–99 However, although remis-
sions can be achieved, responses are usually short-lived.93–99 A sum-
mary of interventional treatment approaches in advanced SM in the
human and canine system is depicted in Table 4.
Concomitant treatment with H1- and H2-blockers is recom-
mended to prevent mediator-related side effects in all patients.100,101
Whether the use of proton-pump inhibitors may improve the symp-
tomatic treatment effect in canine MCT patients like in human SM
patients remained to be evaluated in future clinical trials.61
6.2 | Concluding remarks and future perspectives
Comparative oncology is an emerging field that supports the develop-
ment of new diagnostic and therapeutic concepts in various tumour
models. One example highlighted in this report is comparative
research in human and canine MC neoplasms. In both species, indo-
lent and aggressive disease variants have been described and in both
species, advanced MC neoplasms are often treated by cytoreductive
drugs and KIT-targeting TKI. However, in both species, there is still a
need to develop improved diagnostic criteria, improved prognostica-
tion models, and better (curative) drug therapies. We strongly believe
that comparative oncology approaches may support these develop-
ments. Likewise, based on the higher frequency of canine MCTs,
in vivo studies with various drugs and drug combinations may be more
feasible in dogs with high grade and/or metastasized MCTs than in
human patients with advanced SM. On the other hand, diagnostic and
prognostic parameters developed into SM criteria in the human sys-
tem such as the KIT mutational status, the aberrant expression of sur-
face markers (CD2, CD25, and/or CD30) or the serum tryptase level,
should be tested for their diagnostic and/or prognostic value in canine
MCT. Whether comparative studies will indeed lead to improved
prognostication and therapy in canine and human patients with MC
neoplasms remains to be determined in forthcoming investigations.
Such comparative strategies require an interdisciplinary dialogue
between human and veterinary medicine.
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